EUVIMEDEUVIMED entdecken
Crossref

The value of maintenance therapy in intermediate‐risk non‐muscle‐invasive bladder cancer

Paolo Zaurito iD, Pietro Scilipoti iD, Mattia Longoni, Alessandro Viti, Mario de Angelis iD, Alfonso Santangelo, Giovanni Tremolada iD, Leonardo Quarta iD, Andrea Cosenza, Angelo Occhi, Armando Galdieri, Natasha Disabato und 8 weitere

BJU International · 2026

DOI: 10.1111/bju.16905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2026. Verfasst von Paolo Zaurito und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Maintenance Chemotherapy, Adjuvants, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate which subgroups of patients with intermediate‐risk non‐muscle‐invasive bladder cancer (IR‐NMIBC) benefit from maintenance therapy based on the International Bladder Cancer Group (IBCG) risk stratification, as the role of a maintenance course in patients with IR‐NMIBC is debated. Patients and Methods We relied on a prospectively maintained database of patients with IR‐NMIBC who received intravesical chemotherapy or Bacillus Calmette–Guérin (BCG) (2010–2023). Patients were stratified according the IBCG prognostic algorithm (no, one to two, and three or more risk factors). All patients received at least six induction instillations after index transurethral resection of bladder tumour. We used 3‐month landmark stacked cumulative incidence and multivariable Cox regression models to assess the benefit from a maintenance course in terms of risk of recurrence and progression according to the IBCG risk groups stratification.

Results

Among 464 patients, 205 (44%) received BCG treatment and 259 (56%) received intravesical chemotherapy. The median (interquartile range) number of maintenance instillations was 9 (5–11). Over a median follow‐up of 57 months, 139 (30%) patients had a recurrence. Patients with no IBCG risk factors had a similar risk of 5‐year disease recurrence according to treatment duration (7.7% vs 7.3%; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.49–1.37, for induction only vs induction plus maintenance, respectively), whereas patients with one to two (5‐year risk: 16% vs 13%; HR 0.65, 95% CI 0.48–0.82) or three or more IBCG risk factors (5‐year risk: 21% vs 17%; HR 0.48, 95% CI 0.25–0.85) were associated with lower hazards of recurrence if treated with an induction plus maintenance course.

Conclusions

The IBCG algorithm effectively stratifies patients with IR‐NMIBC by recurrence risk. In this observational cohort, maintenance therapy was associated with lower recurrence rates in patients with one to two or three or more IBCG risk factors, but not in those with no risk factors. These findings suggest that the IBCG stratification may inform risk‐adapted treatment decisions in patients with IR‐NMIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineMaintenance ChemotherapyAdjuvants, ImmunologicHumansMaleFemaleAgedMiddle AgedAdministration, IntravesicalNeoplasm InvasivenessRisk AssessmentNeoplasm Recurrence, LocalRisk FactorsAged, 80 and overNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Bacillus Calmette–GuérinInternational Bladder Cancer Groupbladder cancerintermediate‐riskintravesical chemotherapymaintenancenon‐muscle‐invasive bladder cancer

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Division of Oncology, Department of Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.

ORCID-Profile: Paolo Zaurito, Pietro Scilipoti, Mario de Angelis, Giovanni Tremolada, Leonardo Quarta, Maurizio Colecchia, Andrea Salonia, Francesco Montorsi

Zitieren

APA

Zaurito, P., Scilipoti, P., Longoni, M., Viti, A., de Angelis, M., Santangelo, A., Tremolada, G., Quarta, L., Cosenza, A., Occhi, A., Galdieri, A., Disabato, N., Brancaccio, M., Burgio, G., Necchi, A., Colecchia, M., Salonia, A., Montorsi, F., Briganti, A., & Moschini, M. (2026). The value of maintenance therapy in intermediate‐risk non‐muscle‐invasive bladder cancer. BJU International. https://doi.org/10.1111/bju.16905

Vancouver

Zaurito P, Scilipoti P, Longoni M, Viti A, de Angelis M, Santangelo A, et al. The value of maintenance therapy in intermediate‐risk non‐muscle‐invasive bladder cancer. BJU International. 2026. doi:10.1111/bju.16905

BibTeX
@article{Zaurito2026,
  author = {Zaurito, Paolo and Scilipoti, Pietro and Longoni, Mattia and Viti, Alessandro and de Angelis, Mario and Santangelo, Alfonso and Tremolada, Giovanni and Quarta, Leonardo and Cosenza, Andrea and Occhi, Angelo and Galdieri, Armando and Disabato, Natasha and Brancaccio, Michele and Burgio, Giusy and Necchi, Andrea and Colecchia, Maurizio and Salonia, Andrea and Montorsi, Francesco and Briganti, Alberto and Moschini, Marco},
  title = {The value of maintenance therapy in intermediate‐risk non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.16905}
}
Kostenlos starten →